Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

AmInnovation

Financiado

Cerrado

Disruptive Innovation to Treat Alzheimer s and Parkinson s diseases new target...

Disruptive Innovation to Treat Alzheimer s and Parkinson s diseases new target new patented drug new therapeutic strategy. Neurodegenerative disorders represent the most important medical, social and financial challenges for the 21st century. In 2018, the world counts 50 million people with Alzheimer’s disease and 7 million with Parkinson’s disease, a... ver más

30/11/2019

AMYPORE

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

AMYPORE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-11-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

AMYPORE

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ADPROGRES Alzheimer disease progression Molecular studies of Abeta am... 75K€ Cerrado

PID2021-126715OB-I00 IMPLICACIONES DE LA PROTEINA PRECURSORA AMILOIDE (APP): NEUR... 236K€ Cerrado

GALOMOD Gamma-secretase allosteric modulation as preventive therapy... Cerrado

SAF2016-75768-R ENFERMEDADES DE ALZHEIMER Y PARKINSON: DEGENERACION NEURONAL... 109K€ Cerrado

SAF2015-64948-C2-1-R FARMACOS INNOVADORES PARA ENFERMEDADES NEURODEGENERATIVAS (A... 182K€ Cerrado

PID2020-115613RA-I00 IDENTIFICACION DE NUEVAS DIANAS TERAPEUTICAS EN DEMENCIA 184K€ Cerrado

Duración del proyecto: 6 meses Fecha Inicio: 2019-05-24
Fecha Fin: 2019-11-30

Líder del proyecto

AMYPORE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Neurodegenerative disorders represent the most important medical, social and financial challenges for the 21st century. In 2018, the world counts 50 million people with Alzheimer’s disease and 7 million with Parkinson’s disease, and the number of cases will double before 2050. The current medical paradigms, which incriminate amyloid plaques as the main culprits of these pathologies, do not provide a cure or even stop the progression of the diseases. All clinical trials based on anti-plaques immunotherapies have been unsuccessful. The reason for this global failure is quite simple: these strategies are based on the wrong targets. Indeed, there is no correlation at all between the neurological symptoms and the presence of amyloid plaques in the brain. Thus, the paradigm linking amyloid plaques to neurodegenerative diseases has been totally wrong. AmyPore action plan has been totally different from these unsuccessful approaches. Firstly, we rely on top-level academic researchers who identified the real molecular mechanisms that are the direct cause of the diseases: the amyloid protein oligomers which are responsible for an overdose of calcium in brain cells (amyloid pores). Secondly, AmyPore has taken advantages of the recent artificial intelligence revolutions in neurosciences for identifying a new biological code and optimizing the design of AmyPore lead product candidate. AmyPore solution, called AmyP53 is the disruptive innovation that has demonstrated to be in the position to overcome these terrible diseases. As a matter of fact, relying upon : - an exclusive license, linked to an international patent owned by the inventors, - recent scientific publications, - and additional recent conclusive tests, AmyP53 is : - easy to test, - easy to produce worldwide, - easy to administer. AmyP53 is not only one of the first drug that targets the oligomer cascade, it is the only one that can block the formation neurotoxic oligomers in the membrane of brain cells.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores